NCT01682564 - To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure | Biotech Hunter

Enrollment

169

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

HypertensionCongestive Heart Failure

Interventions

DRUG

Candemore tablet

"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"

DRUG

Atacand tablet

"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"

Trial Locations (14)

614-735

Inje university pusan hospital, Busan

660-702

Gyeongsang national university hospital, Jinju

701-724

Daegu fatima hospital, Daegu

607-711

Daedong hospital, Busan

612-030

Inje university haeundae paik hospital, Busan

600-730

Maryknoll medical center, Busan

700-712

Keimyung university dongsan medical center, Daegu

700-721

Kyungpook national university hospital, Daegu

630-723

Samsung changwon hospital, Changwon

705-717

Yeungnam university medical center, Daegu

705-718

Daegu catholic univ. medical center, Daegu

602-702

Kosin university gospel hospital, Busan

602-715

Dong-A university medical center, Busan

780-350

Dongguk university gyeongju hospital, Gyeongju